<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE collection SYSTEM "BioC.dtd"><collection><source>BioC-API</source><date>20260207</date><key>collection.key</key><document><id>PMC12754609</id><infon key="license">CC BY</infon><passage><infon key="article-id_doi">10.5152/ArchRheumatol.2025.25192</infon><infon key="article-id_pmc">PMC12754609</infon><infon key="article-id_publisher-id">ar-40-4-413</infon><infon key="fpage">413</infon><infon key="issue">4</infon><infon key="kwd">Arthritis autoimmune disease dysbiosis gut-joint axis intestinal permeability microbiome rheumatology Th17 Treg balance</infon><infon key="license">
 Content of this journal is licensed under a Creative Commons Attribution 4.0 International License.
</infon><infon key="lpage">421</infon><infon key="name_0">surname:Şahin;given-names:Nilay</infon><infon key="name_1">surname:Salbaş;given-names:Ender</infon><infon key="section_type">TITLE</infon><infon key="title">Keywords</infon><infon key="type">front</infon><infon key="volume">40</infon><infon key="year">2025</infon><offset>0</offset><text>The Gut-Joint Connection: Microbiome’s Role in Rheumatic Disease</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>67</offset><text>The human gut microbiome is a pivotal regulator of systemic immunity and a central factor in the pathogenesis of rheumatic diseases. An imbalance in this microbial community, known as “dysbiosis,” can trigger and perpetuate autoimmune responses through the “gut-joint axis.” A key mechanism underpinning this connection is increased intestinal permeability (“leaky gut”), which facilitates the translocation of microbial products like lipopolysaccharide into the systemic circulation, thereby provoking chronic inflammation. Concurrently, dysbiosis disrupts the critical homeostatic balance between pro-inflammatory Th17 cells and regulatory T cells, an immunological hallmark of conditions such as rheumatoid arthritis (RA), ankylosing spondylitis, and systemic lupus erythematosus (SLE).</text></passage><passage><infon key="section_type">ABSTRACT</infon><infon key="type">abstract</infon><offset>869</offset><text>Specific microbial signatures, including the expansion of Prevotella copri in RA and Ruminococcus gnavus in SLE, are emerging as potential diagnostic biomarkers. This deeper understanding is paving the way for innovative therapeutic strategies. Interventions aimed at modulating the gut microbiota, such as targeted diets, probiotics, prebiotics and fecal microbiota transplantation, represent a promising frontier for the personalized management of rheumatic diseases. This review explores the foundational mechanisms linking the microbiome to autoimmunity and discusses the clinical potential of harnessing the gut-joint axis to improve patient outcomes.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>1526</offset><text>Main Points</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1538</offset><text>In the pathogenesis of rheumatic diseases, an imbalance in the gut microbiota (dysbiosis) is not just a consequence but also a central triggering factor.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1692</offset><text>Increased intestinal permeability (“leaky gut”) is a key mechanism leading to the entry of microbial products (e.g., lipopolysaccharide) into the systemic circulation and triggering chronic inflammation.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>1900</offset><text>The microbiome modulates the sensitive balance between pro-inflammatory (Th17) and anti-inflammatory regulatory T cells in the immune system, and disruption of this balance intensifies autoimmune responses.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2107</offset><text>The “gut-joint axis” concept explains how events in the gut directly affect joint health through systemic inflammation, immune cell migration, and microbial metabolites.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2281</offset><text>Targeting the microbiome offers significant potential for innovative and personalized treatment strategies, including diet, probiotics, prebiotics and fecal microbiota transplantation (FMT).</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>2472</offset><text>Introduction and Basic Mechanisms</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>2506</offset><text>The human body harbors an ecosystem comprising human cells alongside bacteria, archaea, viruses, and fungi, termed the human microbiome. The majority of the microbial load resides in the large intestine, hosting &gt;1500 species across &gt;50 phyla, with Bacteroidetes and Firmicutes constituting the bulk of adult gut bacteria. The microbiota maintains a symbiotic “eubiosis” balance with the host, performing metabolic, protective, and immune-regulatory functions: fermentation of fibers, vitamin synthesis, and short-chain fatty acid (SCFA) production; prevention of pathogen colonization and support of barrier integrity; and education of mucosal immune responses are among the primary ones. These mutual interactions have heightened interest in the microbiome’s role in the etiology of autoimmune and rheumatic diseases.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>3332</offset><text>Barrier Integrity and “Leaky Gut”</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>3370</offset><text>Tight junctions in the intestinal epithelium limit passage from the lumen to systemic circulation; disruption of zonulin-mediated regulation increases permeability, allowing microbial products such as lipopolysaccharide (LPS) to leak and elevate tumor necrosis factor-α (TNF-α)/Interleukin-6 (IL-6) production via the TLR4–MyD88 pathway, thereby amplifying systemic inflammation. In ankylosing spondylitis (AS), epithelial and vascular barrier disruption with elevated zonulin levels has been reported; similarly, increased permeability consistent with dysbiosis has been noted in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). This barrier dysfunction contributes to microbial product leakage and peripheral immune tolerance breakdown, supporting autoantigenic stimulation and heightened immune signaling (Figure 1).</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>4215</offset><text>Helper T 17/Regulatory T Balance</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4248</offset><text>The gut microbiota regulates the balance between helper T 17 (Th17) and regulatory T (Treg) cells, which play a central role in the pathogenesis of rheumatic diseases. The Th17 cells produce IL-17 to promote autoimmune inflammation, whereas Treg cells maintain immune tolerance. Gut dysbiosis disrupts this balance. For instance, segmented filamentous bacteria colonization activates Th17 cells, whereas certain commensals like Bacteroides fragilis can restore equilibrium. The SCFAs, particularly butyrate, support Treg cell formation, exerting immunomodulatory effects and limiting autoimmune responses. This Th17/Treg imbalance is a fundamental feature of many autoimmune diseases, including RA, SLE, and AS.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>4960</offset><text>Microbial Metabolites</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>4982</offset><text>Molecules produced by the microbiota, such as SCFAs, tryptophan metabolites, and bile acids, profoundly influence host physiology and immune responses. Short-chain fatty acids, generated from dietary fiber fermentation, include butyrate, which possesses potent anti-inflammatory properties. Butyrate mitigates inflammation and bone loss in conditions like osteoarthritis (OA), AS, and RA by regulating Treg cells and improving gut barrier function. Indoles from tryptophan metabolism act via the aryl hydrocarbon receptor (AhR) in immune modulation. In patients with RA, anti-inflammatory tryptophan metabolites decrease, whereas pro-inflammatory metabolites increase.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>5651</offset><text>Molecular Mimicry</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>5669</offset><text>This mechanism triggers autoimmunity through the structural resemblance between microbial antigens and host proteins. For example, enolase produced by Porphyromonas gingivalis, which is associated with RA, can elicit autoimmunity against human enolase. Similarly, strains of Ruminococcus gnavus linked to SLE may initiate cross-reactive immune responses against host double-stranded DNA (dsDNA). Aggregatibacter actinomycetemcomitans induces citrullination, linking periodontal infection to RA autoimmunity. This illustrates how even normal microbial community members can prompt the immune system to attack the host tissues.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>6295</offset><text>Gut-Joint Axis</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>6310</offset><text>This concept denotes a bidirectional relationship between the gut microbiota and joint health. Gut microbiota dysbiosis contributes to the development of various joint diseases, including RA, AS, psoriatic arthritis (PsA), and OA. The axis functions through mechanisms like systemic inflammation from leaky gut, circulation of microbial metabolites like SCFAs to joints, and migration of gut-activated immune cells to joints. In germ-free (microbe-free) animal models, particularly HLA-B27 transgenic mice, the prevention of gut and joint inflammation strongly supports the central role of the microbiota in these diseases.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>6934</offset><text>Inflammatory Arthritides and Microbiome Dysbiosis</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>6984</offset><text>Evidence is mounting that imbalances in the gut and oral microbiota play critical roles in the pathogenesis of inflammatory arthritides. Microbiome dysbiosis is strongly associated with the onset and progression of these diseases (Table 1).</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>7225</offset><text>Rheumatoid Arthritis and Microbiome Dysbiosis</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>7271</offset><text>In RA, autoimmune responses are thought to originate from the mucosal surfaces. Patients with RA exhibit a profile in both oral and gut microbiota characterized by reduced beneficial bacteria and increased pro-inflammatory bacteria.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_3</infon><offset>7504</offset><text>Gut Dysbiosis: Increased Prevotella copri and Decreased Faecalibacterium prausnitzii:</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>7590</offset><text>In RA patients, particularly those with new-onset RA, an increase in Prevotella copri has been observed. P. copri is identified as a pro-inflammatory bacterium that exacerbates arthritis in experimental models and promotes T-cell differentiation into Th17 cells, fueling systemic inflammation. Conversely, beneficial bacteria like Faecalibacterium prausnitzii, which possess anti-inflammatory properties and produce butyrate, are decreased.  Faecalibacterium prausnitzii has been shown to alleviate inflammatory arthritis in experimental models. This imbalance can lead to impaired gut barrier function and systemic inflammation.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_3</infon><offset>8220</offset><text>Oral Microbiome: Role of Porphyromonas gingivalis, Citrullination, and anti-citrullinated protein Antibodies:</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>8330</offset><text>The oral microbiome, particularly through periodontal diseases, plays a significant role in RA pathogenesis. Porphyromonas gingivalis, a key pathogen in periodontal disease, is associated with RA onset. This bacterium citrullinates proteins via its unique microbial peptidylarginine deiminase enzyme, triggering the production of anti-citrullinated protein antibodies (ACPA). These ACPAs cross-react with human citrullinated peptides, thereby initiating autoimmunity. The ACPA-positive individuals have an increased risk of RA, often accompanied by a dysbiotic oral microbiome with elevated levels of P. gingivalis.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>8946</offset><text>Axial Spondyloarthritis, Psoriatic Arthritis, and Microbiome Dysbiosis</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>9017</offset><text>Axial spondyloarthritis (AxSpA) and PsA are inflammatory arthritides closely linked to the gut microbiome. There is a strong clinical and genetic connection between these diseases and inflammatory bowel disease (IBD).,63 Dysbiotic features observed in patients with IBD, such as reduced phylogenetic diversity, lower Firmicutes proportion and particularly decreased F. prausnitzii, are also seen in patients with PsA.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>9435</offset><text>Subclinical gut inflammation is common in patients with AxSpA and PsA. HLA-B27 transgenic rats do not develop inflammation under germ-free conditions, suggesting that commensal bacteria are triggers. The IL-23/IL-17 signaling pathway plays a central role in AxSpA pathogenesis, and microbial signals can activate this pathway. Microbiota dysbiosis drives immune dysregulation by shifting T cell differentiation toward a Th17-dominant phenotype and increasing IL-17 production. Specific microbial differences have been identified in both AxSpA and PsA;</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>9987</offset><text>Axial spondyloarthritis: Reduced bacterial diversity with increased abundance of genera such as Klebsiella, R. gnavus, and Streptococcus and decreased abundance of Dialister and Faecalibacterium. Additionally, Proteobacteria and Pasteurellaceae levels were normalized after TNF inhibitor therapy.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>10284</offset><text>Psoriatic arthritis: Reduced bacterial diversity, similar to IBD., Increased Actinobacteria phylum and decreased Rikenellaceae family.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>10419</offset><text>Evidence in Other Diseases</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>10446</offset><text>Systemic Lupus Erythematosus</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>10475</offset><text>Patients with SLE exhibit marked changes in the gut microbiota, with a decreased abundance of Firmicutes and an increased abundance of Bacteroidetes. Notably, R. gnavus abundance increases during active disease periods and correlates with disease activity. Antibodies against R. gnavus may cross-react with host DNA, triggering anti-dsDNA antibody responses. Increased intestinal permeability and abnormalities in Type I interferon production are key contributors to SLE pathogenesis.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>10960</offset><text>Sjögren’s Syndrome</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>10982</offset><text>Sjögren’s syndrome (SS) is associated with distinct changes in both oral and intestinal microbiota. Oral dysbiosis in the oral microbiota and severe dysbiosis in the gut microbiota are common and correlate with systemic disease activity. Similar to RA and SLE, SS shows common alterations like decreased anti-inflammatory butyrate-producing bacteria (e.g., Faecalibacterium) and increased pro-inflammatory bacteria (e.g., Streptococcus).</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>11423</offset><text>Systemic Sclerosis</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>11442</offset><text>In systemic sclerosis (SSc), a unique gut microbial composition is identified, with decreased protective butyrate-producing bacteria and increased harmful genera like Fusobacterium. Increased intestinal permeability may also play a role in the pathogenesis of SSc.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>11707</offset><text>Vasculitides and Metabolic Diseases</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>11743</offset><text>Children with IgA vasculitis (HSP) have been found to have increased abundance of Fusobacteria and decreased abundance of Firmicutes. Behçet’s disease shows changes toward increased abundance of Bifidobacteria in the gut. Osteoarthritis, traditionally considered non-inflammatory, is now linked to low-grade systemic inflammation (metaflammation) and gut microbiota. Leaked LPS from the gut can initiate obesity-related inflammation, worsening OA progression. In Gout, the microbiome’s impact on purine metabolism and uric acid levels is under investigation, with reduced microbial diversity observed in patients.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>12362</offset><text>Factors Influencing the Microbiome: Diet, Lifestyle, and Medications</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>12431</offset><text>Understanding the factors that shape the composition and function of the microbiome can offer new strategies for disease management. These factors primarily include diet, lifestyle, and medications.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>12630</offset><text>Diet and Metabolism: Primary Shapers of the Microbiome</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>12685</offset><text>Diet is one of the most potent environmental factors that can rapidly alter the gut microbiota composition. Western-style diets that are low in fiber and high in fat can lead to pro-inflammatory changes by reducing butyrate-producing bacteria. In contrast, fiber-rich diets (prebiotics) and fermented foods (probiotics) enhance SCFA production and modulate the immune system, providing benefits. Particularly, butyrate can inhibit systemic inflammation by activating Treg cells and strengthening the gut barrier. Strategies such as fecal microbiota transplantation (FMT) also hold promise for correcting dysbiosis.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>13300</offset><text>Lifestyle and Medications: Interactions on the Microbiome</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>13358</offset><text>Smoking can contribute to oral microbiome dysbiosis, while chronic stress adversely affects the gut-brain axis. Medications have a strong effect on the microbiome. Antibiotics are the most potent agents that alter microbiota composition and diversity. Nonsteroidal anti-inflammatory drugs and proton pump inhibitors can damage the gut barrier and alter the microbiome composition, contributing to inflammation. Disease-modifying antirheumatic drugs and biologics can modulate the microbiome. For example, methotrexate and sulfasalazine may reduce the levels of B. fragilis and Enterobacteriaceae in the gut. The TNF inhibitors can increase microbiota diversity in patients with AS, approximating a healthy profile. Janus kinase inhibitors, such as tofacitinib, are associated with significant changes in certain gut bacterial lineages in patients with PsA and may exert therapeutic effects by modulating plasma metabolites and the gut microbiota.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_1</infon><offset>14305</offset><text>Microbiome Research in Special Populations, Pain, Virome, and Cardiovascular Comorbidities</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>14396</offset><text>Microbiome research extends beyond bacteria to include viruses (virome) and fungi (mycobiome), which broadens the understanding of disease pathogenesis.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>14549</offset><text>The microbiome shaped during early life is critical for immune system development. Marked dysbiosis in both oral and gut microbiota has been observed in childhood autoimmune diseases, such as juvenile idiopathic arthritis (JIA). Notably, reductions in beneficial butyrate-producing bacteria, such as F. prausnitzii, highlight the potential of microbiome-based approaches in JIA treatment.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>14938</offset><text>In chronic pain conditions like fibromyalgia (FMS), the gut microbiome plays a critical role in pathogenesis via the “gut-brain axis.” Metabolites produced by gut microbes, such as SCFAs, can directly or indirectly influence the central nervous system and modulate pain perception. This may be a common denominator in comorbid conditions like FMS, chronic fatigue syndrome, and irritable bowel syndrome.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>15346</offset><text>The unseen aspects of the microbiome, including the virome and mycobiome, also contribute to autoimmunity. Viruses like Epstein-Barr virus may initiate autoimmune responses through molecular mimicry. Similarly, changes in gut fungal composition (mycobiome) are thought to play a role in diseases like IBD and modulate immune responses.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>15682</offset><text>Cardiovascular Comorbidities in Rheumatic Diseases</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>15733</offset><text>Rheumatic diseases often co-occur with cardiovascular diseases due to systemic effects of chronic inflammation. This systemic inflammation is closely linked to endothelial cell activation and atherosclerosis. The ability of the microbiome to modulate inflammatory responses is a key mechanism linking rheumatic diseases and cardiovascular comorbidities.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">title_2</infon><offset>16087</offset><text>Role of Animal Models in Understanding Mechanisms and Limitations in Translation to Human Studies</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>16185</offset><text>Animal models, particularly gnotobiotic models (germ-free or colonized with known microorganisms), are indispensable for studying host-microorganism interactions. For instance, destabilization of the medial meniscus mouse models demonstrated that gut microbiome dysbiosis accelerates OA progression. Experiments using “humanized” germ-free SKG mice with human gut microbiota revealed that protein tyrosine phosphatase non-receptor type 2 haploinsufficiency variably exacerbates mannan-induced arthritis when colonized with feces from RA patients, showing increased T cell-driven inflammation in the joints. Similarly, dextran sulfate sodium-induced colitis models and collagen-induced arthritis models are used to examine the effects of microbiota on inflammation.</text></passage><passage><infon key="section_type">INTRO</infon><infon key="type">paragraph</infon><offset>16954</offset><text>However, translating the findings from animal models to humans faces significant limitations. The most prominent constraint is the difference in bacterial composition between humans and animals. Additionally, host genetics and environmental factors may not fully reflect the complex disease phenotypes seen in humans. Thus, while animal models are critical for mechanistic insights, rigorous human studies are essential for clinical application.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">title_1</infon><offset>17400</offset><text>Clinical Horizons and Conclusion</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>17433</offset><text>The microbiome has emerged as a potential biomarker source for disease diagnosis, prognosis prediction, and treatment response determination. For example, the microbiome composition in patients with FMS can be distinguished from that in healthy individuals with high accuracy. Distinct microbiota and metabolite profiles have been identified among different uveitis types. Specific bacterial species like Bacteroides caecimuris, Mediterranea massilliensis, Bacteroides coprophilus, Clostridium_sp_7_3_54FAA and Bifidobacterium bifidum may aid in differentiating patients with SS from healthy individuals and correlate with disease severity. In patients with AS, species such as R. gnavus could serve as markers, with TNF inhibitor therapy shifting the microbiome toward a healthy profile.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>18222</offset><text>However, most current studies are correlational and insufficient to prove causality. Methodological variations and population heterogeneity also limit generalizability.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>18391</offset><text>Therapeutic strategies, including dietary interventions, prebiotics, probiotics, postbiotics (SCFAs), and FMT, show promise. Probiotics have demonstrated the potential to improve inflammation and symptoms. SCFAs, such as butyrate, have been shown to reverse bone loss and reduce inflammation in animal models. The FMT, proven effective in Clostridioides difficile infections, also yields encouraging results in autoimmune diseases such as SLE and RA.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>18842</offset><text>The greatest challenges in fully harnessing the microbiome in clinical practice include distinguishing causality from correlation, overcoming inter-study heterogeneity, and understanding each individual’s unique microbiome structure. In the future, personalized treatment strategies that integrate microbiota profiling, host genetics, and other factors could redefine therapeutic paradigms for rheumatic and other chronic diseases.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">paragraph</infon><offset>19276</offset><text>In conclusion, the gut microbiota is an indispensable player in human health and disease. As knowledge in this field translates to clinical practice, it holds immense potential for the diagnosis, prognosis, and treatment of diseases. Future research should facilitate the integration of microbiome-based therapies into clinical routines using personalized and targeted strategies. The microbiome opens doors to a new era of a healthier future in medicine.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">footnote</infon><offset>19732</offset><text>Peer-review: Externally peer-reviewed.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">footnote</infon><offset>19771</offset><text>Author Contributions: Concept – E.S., N.Ş.; Design – E.S., N.Ş.; Supervision – N.Ş.; Resources – E.S.; Materials – E.S.; Data Collection and/or Processing – E.S.; Analysis and/or Interpretation – E.S.; Literature Search – E.S.; Writing – E.S., N.Ş.; Critical Review – E.S., N.Ş.</text></passage><passage><infon key="section_type">CONCL</infon><infon key="type">footnote</infon><offset>20075</offset><text>Declaration of Interests: The authors have no conflicts of interest to declare.</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">title_1</infon><offset>20155</offset><text>Data Availability Statement:</text></passage><passage><infon key="section_type">SUPPL</infon><infon key="type">paragraph</infon><offset>20184</offset><text>The data that support the findings of this study are available on request from the corresponding author.</text></passage><passage><infon key="section_type">REF</infon><infon key="type">title</infon><offset>20289</offset><text>References</text></passage><passage><infon key="name_0">surname:Song;given-names:Z</infon><infon key="name_1">surname:Song;given-names:R</infon><infon key="name_2">surname:Liu;given-names:Y</infon><infon key="name_3">surname:Wu;given-names:Z</infon><infon key="name_4">surname:Zhang;given-names:X</infon><infon key="pub-id_doi">10.1016/j.foodres.2023.112730</infon><infon key="section_type">REF</infon><infon key="source">Food Res Int</infon><infon key="type">ref</infon><infon key="volume">167</infon><infon key="year">2023</infon><offset>20300</offset><text>Effects of ultra-processed foods on the microbiota-gut-brain axis: the bread-and-butter issue</text></passage><passage><infon key="fpage">554</infon><infon key="issue">7</infon><infon key="name_0">surname:La Placa;given-names:G</infon><infon key="name_1">surname:Covino;given-names:M</infon><infon key="name_2">surname:Candelli;given-names:M</infon><infon key="name_3">surname:Gasbarrini;given-names:A</infon><infon key="name_4">surname:Franceschi;given-names:F</infon><infon key="name_5">surname:Merra;given-names:G</infon><infon key="pub-id_doi">10.3390/cells14070554</infon><infon key="pub-id_pmid">40214507</infon><infon key="section_type">REF</infon><infon key="source">Cells</infon><infon key="type">ref</infon><infon key="volume">14</infon><infon key="year">2025</infon><offset>20394</offset><text>The impact of microbiota on musculoskeletal injuries</text></passage><passage><infon key="fpage">4032</infon><infon key="issue">23</infon><infon key="name_0">surname:Saponaro;given-names:F</infon><infon key="name_1">surname:Bertolini;given-names:A</infon><infon key="name_2">surname:Baragatti;given-names:R</infon><infon key="pub-id_doi">10.3390/nu16234032</infon><infon key="pub-id_pmid">39683426</infon><infon key="section_type">REF</infon><infon key="source">Nutrients</infon><infon key="type">ref</infon><infon key="volume">16</infon><infon key="year">2024</infon><offset>20447</offset><text>Myokines and microbiota: new perspectives in the endocrine muscle-gut axis</text></passage><passage><infon key="fpage">ard-2024-226362</infon><infon key="name_0">surname:Rooney;given-names:CM</infon><infon key="name_1">surname:Jeffery;given-names:IB</infon><infon key="name_2">surname:Mankia;given-names:K</infon><infon key="name_3">surname:Wilcox;given-names:MH</infon><infon key="name_4">surname:Emery;given-names:P</infon><infon key="pub-id_doi">10.1136/ard-2024-226362</infon><infon key="section_type">REF</infon><infon key="source">Ann Rheum Dis</infon><infon key="type">ref</infon><infon key="year">2024</infon><offset>20522</offset><text>Dynamics of the gut microbiome in individuals at risk of rheumatoid arthritis: a cross-sectional and longitudinal observational study</text></passage><passage><infon key="fpage">1226</infon><infon key="issue">4</infon><infon key="lpage">1238</infon><infon key="name_0">surname:Gilat;given-names:R</infon><infon key="name_1">surname:Yazdi;given-names:AA</infon><infon key="name_2">surname:Weissman;given-names:AC</infon><infon key="pub-id_doi">10.1016/j.arthro.2024.05.010</infon><infon key="pub-id_pmid">38797504</infon><infon key="section_type">REF</infon><infon key="source">Arthroscopy</infon><infon key="type">ref</infon><infon key="volume">41</infon><infon key="year">2025</infon><offset>20656</offset><text>The gut microbiome and joint microbiome show alterations in patients with knee osteoarthritis versus controls: A systematic review</text></passage><passage><infon key="fpage">3705</infon><infon key="issue">21</infon><infon key="name_0">surname:Ciancarelli;given-names:I</infon><infon key="name_1">surname:Morone;given-names:G</infon><infon key="name_2">surname:Iosa;given-names:M</infon><infon key="name_3">surname:Cerasa;given-names:A</infon><infon key="name_4">surname:Calabrò;given-names:RS</infon><infon key="name_5">surname:Tozzi Ciancarelli;given-names:MG</infon><infon key="pub-id_doi">10.3390/nu16213705</infon><infon key="pub-id_pmid">39519537</infon><infon key="section_type">REF</infon><infon key="source">Nutrients</infon><infon key="type">ref</infon><infon key="volume">16</infon><infon key="year">2024</infon><offset>20787</offset><text>Neuronutrition and its impact on post-stroke neurorehabilitation: modulating plasticity through diet</text></passage><passage><infon key="name_0">surname:Ran;given-names:C</infon><infon key="name_1">surname:Xu;given-names:Y</infon><infon key="name_2">surname:Wang;given-names:Q</infon><infon key="pub-id_doi">10.1016/j.micpath.2025.107911</infon><infon key="section_type">REF</infon><infon key="source">Microb Pathog</infon><infon key="type">ref</infon><infon key="volume">207</infon><infon key="year">2025</infon><offset>20888</offset><text>Gut microbiota from osteoarthritic patients without obesity aggravates osteoarthritis progression in rats by enriching acetic acid</text></passage><passage><infon key="fpage">RP89862</infon><infon key="name_0">surname:Veseli;given-names:I</infon><infon key="name_1">surname:Chen;given-names:YT</infon><infon key="name_2">surname:Schechter;given-names:MS</infon><infon key="pub-id_doi">10.7554/eLife.89862</infon><infon key="pub-id_pmid">40377187</infon><infon key="section_type">REF</infon><infon key="source">Elife</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="year">2025</infon><offset>21019</offset><text>Microbes with higher metabolic independence are enriched in human gut microbiomes under stress</text></passage><passage><infon key="fpage">177</infon><infon key="issue">4</infon><infon key="lpage">187</infon><infon key="name_0">surname:Amarnani;given-names:A</infon><infon key="name_1">surname:Silverman;given-names:GJ</infon><infon key="pub-id_doi">10.2478/rir-2023-0027</infon><infon key="pub-id_pmid">38125641</infon><infon key="section_type">REF</infon><infon key="source">Rheumatol Immunol Res</infon><infon key="type">ref</infon><infon key="volume">4</infon><infon key="year">2023</infon><offset>21114</offset><text>Understanding the roles of the microbiome in autoimmune rheumatic diseases</text></passage><passage><infon key="name_0">surname:Li;given-names:Z</infon><infon key="name_1">surname:Wen;given-names:M</infon><infon key="name_2">surname:Tang;given-names:C</infon><infon key="pub-id_doi">10.3389/fmicb.2025.1615884</infon><infon key="section_type">REF</infon><infon key="source">Front Microbiol</infon><infon key="type">ref</infon><infon key="volume">16</infon><infon key="year">2025</infon><offset>21189</offset><text>Gut microbiota orchestrates skeletal muscle development and metabolism in germ-free and SPF pigs</text></passage><passage><infon key="fpage">1246</infon><infon key="issue">8</infon><infon key="lpage">1257</infon><infon key="name_0">surname:Tran;given-names:M</infon><infon key="name_1">surname:Huh;given-names:JR</infon><infon key="name_2">surname:Devlin;given-names:AS</infon><infon key="pub-id_doi">10.1038/s41590-025-02227-2</infon><infon key="pub-id_pmid">40691327</infon><infon key="section_type">REF</infon><infon key="source">Nat Immunol</infon><infon key="type">ref</infon><infon key="volume">26</infon><infon key="year">2025</infon><offset>21286</offset><text>The role of gut microbial metabolites in the T cell lifecycle</text></passage><passage><infon key="fpage">866</infon><infon key="issue">4</infon><infon key="lpage">877</infon><infon key="name_0">surname:Yang;given-names:W</infon><infon key="name_1">surname:Cong;given-names:Y</infon><infon key="pub-id_doi">10.1038/s41423-021-00661-4</infon><infon key="pub-id_pmid">33707689</infon><infon key="section_type">REF</infon><infon key="source">Cell Mol Immunol</infon><infon key="type">ref</infon><infon key="volume">18</infon><infon key="year">2021</infon><offset>21348</offset><text>Gut microbiota-derived metabolites in the regulation of host immune responses and immune-related inflammatory diseases</text></passage><passage><infon key="fpage">10729</infon><infon key="issue">18</infon><infon key="name_0">surname:Belvoncikova;given-names:P</infon><infon key="name_1">surname:Maronek;given-names:M</infon><infon key="name_2">surname:Gardlik;given-names:R</infon><infon key="pub-id_doi">10.3390/ijms231810729</infon><infon key="pub-id_pmid">36142642</infon><infon key="section_type">REF</infon><infon key="source">Int J Mol Sci</infon><infon key="type">ref</infon><infon key="volume">23</infon><infon key="year">2022</infon><offset>21467</offset><text>Gut dysbiosis and fecal microbiota transplantation in autoimmune diseases</text></passage><passage><infon key="name_0">surname:Mo;given-names:C</infon><infon key="name_1">surname:Bi;given-names:J</infon><infon key="name_2">surname:Li;given-names:S</infon><infon key="pub-id_doi">10.1016/j.micres.2024.127613</infon><infon key="section_type">REF</infon><infon key="source">Microbiol Res</infon><infon key="type">ref</infon><infon key="volume">281</infon><infon key="year">2024</infon><offset>21541</offset><text>The influence and therapeutic effect of microbiota in systemic lupus erythematosus</text></passage><passage><infon key="fpage">e53</infon><infon key="issue">8</infon><infon key="lpage">e72</infon><infon key="name_0">surname:Jena;given-names:PK</infon><infon key="name_1">surname:Wakita;given-names:D</infon><infon key="name_2">surname:Gomez;given-names:AC</infon><infon key="pub-id_doi">10.1161/CIRCRESAHA.124.325079</infon><infon key="pub-id_pmid">40026151</infon><infon key="section_type">REF</infon><infon key="source">Circ Res</infon><infon key="type">ref</infon><infon key="volume">136</infon><infon key="year">2025</infon><offset>21624</offset><text>Intestinal microbiota contributes to the development of cardiovascular inflammation and vasculitis in mice</text></passage><passage><infon key="fpage">70</infon><infon key="issue">1</infon><infon key="lpage">80</infon><infon key="name_0">surname:Long;given-names:A</infon><infon key="name_1">surname:Kleiner;given-names:A</infon><infon key="name_2">surname:Looney;given-names:RJ</infon><infon key="pub-id_doi">10.1016/j.jaci.2022.11.001</infon><infon key="pub-id_pmid">36608984</infon><infon key="section_type">REF</infon><infon key="source">J Allergy Clin Immunol</infon><infon key="type">ref</infon><infon key="volume">151</infon><infon key="year">2023</infon><offset>21731</offset><text>Immune dysregulation</text></passage><passage><infon key="fpage">9</infon><infon key="issue">1</infon><infon key="lpage">13</infon><infon key="name_0">surname:Scher;given-names:JU</infon><infon key="name_1">surname:Nayak;given-names:R</infon><infon key="name_2">surname:Clemente;given-names:JC</infon><infon key="pub-id_doi">10.1136/ard-2024-225735</infon><infon key="pub-id_pmid">39874238</infon><infon key="section_type">REF</infon><infon key="source">Ann Rheum Dis</infon><infon key="type">ref</infon><infon key="volume">84</infon><infon key="year">2025</infon><offset>21752</offset><text>Microbiome research in autoimmune and immune-mediated inflammatory diseases: lessons, advances and unmet needs</text></passage><passage><infon key="fpage">312</infon><infon key="issue">3</infon><infon key="lpage">323</infon><infon key="name_0">surname:Moulin;given-names:D</infon><infon key="name_1">surname:Millard;given-names:M</infon><infon key="name_2">surname:Taïeb;given-names:M</infon><infon key="pub-id_doi">10.1136/ard-2023-224014</infon><infon key="pub-id_pmid">38049981</infon><infon key="section_type">REF</infon><infon key="source">Ann Rheum Dis</infon><infon key="type">ref</infon><infon key="volume">83</infon><infon key="year">2024</infon><offset>21863</offset><text>Counteracting tryptophan metabolism alterations as a new therapeutic strategy for rheumatoid arthritis</text></passage><passage><infon key="issue">1</infon><infon key="name_0">surname:Liu;given-names:S</infon><infon key="name_1">surname:Xu;given-names:H</infon><infon key="name_2">surname:Liu;given-names:L</infon><infon key="pub-id_doi">10.1186/s13075-025-03602-y</infon><infon key="section_type">REF</infon><infon key="source">Arthritis Res Ther</infon><infon key="type">ref</infon><infon key="volume">27</infon><infon key="year">2025</infon><offset>21966</offset><text>Gut microbiome dysbiosis accelerates osteoarthritis progression by inducing IFP-SM inflammation in &quot;double-hit&quot; mice</text></passage><passage><infon key="name_0">surname:Naveed;given-names:M</infon><infon key="name_1">surname:Atta;given-names:A</infon><infon key="name_2">surname:Rui;given-names:B</infon><infon key="pub-id_doi">10.1016/j.phymed.2025.157079</infon><infon key="section_type">REF</infon><infon key="source">Phytomedicine</infon><infon key="type">ref</infon><infon key="volume">145</infon><infon key="year">2025</infon><offset>22083</offset><text>Combination of Withania coagulans and Fagonia cretica ameliorates hyperuricemia by re-modulating gut microbiota-derived spermidine and traumatic acid</text></passage><passage><infon key="issue">20</infon><infon key="name_0">surname:Liu;given-names:M</infon><infon key="name_1">surname:Li;given-names:M</infon><infon key="name_2">surname:Jin;given-names:S</infon><infon key="name_3">surname:Wang;given-names:X</infon><infon key="name_4">surname:Geng;given-names:J</infon><infon key="name_5">surname:Liu;given-names:X</infon><infon key="pub-id_doi">10.1016/j.heliyon.2024.e39393</infon><infon key="section_type">REF</infon><infon key="source">Heliyon</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="year">2024</infon><offset>22233</offset><text>Differential intestinal microbes and metabolites between Behcet's uveitis and Fuchs syndrome</text></passage><passage><infon key="name_0">surname:Rashid;given-names:M</infon><infon key="name_1">surname:Pereira;given-names:HS</infon><infon key="name_2">surname:Alissa;given-names:A</infon><infon key="pub-id_doi">10.1016/j.bas.2025.104272</infon><infon key="section_type">REF</infon><infon key="source">Brain Spine</infon><infon key="type">ref</infon><infon key="volume">5</infon><infon key="year">2025</infon><offset>22326</offset><text>Microbiome dysbiosis in spinal pathology: mechanisms, evidence, and research limitations</text></passage><passage><infon key="fpage">2793</infon><infon key="issue">7</infon><infon key="lpage">2808</infon><infon key="name_0">surname:Wang;given-names:X</infon><infon key="name_1">surname:Sun;given-names:C</infon><infon key="name_2">surname:Yang;given-names:X</infon><infon key="pub-id_doi">10.1007/s10067-025-07467-z</infon><infon key="pub-id_pmid">40439987</infon><infon key="section_type">REF</infon><infon key="source">Clin Rheumatol</infon><infon key="type">ref</infon><infon key="volume">44</infon><infon key="year">2025</infon><offset>22415</offset><text>Exploring the potential mechanism of tofacitinib therapy for ankylosing spondylitis through gut microbiome and plasma metabolomics</text></passage><passage><infon key="name_0">surname:Sendo;given-names:S</infon><infon key="name_1">surname:Vela;given-names:AJ</infon><infon key="name_2">surname:Ro;given-names:M</infon><infon key="pub-id_doi">10.1016/j.jaut.2025.103452</infon><infon key="section_type">REF</infon><infon key="source">J Autoimmun</infon><infon key="type">ref</infon><infon key="volume">156</infon><infon key="year">2025</infon><offset>22546</offset><text>Interaction between haploinsufficiency of PTPN2 and patient microbiome promotes autoimmune arthritis in mice</text></passage><passage><infon key="name_0">surname:Wang;given-names:Y</infon><infon key="name_1">surname:Wei;given-names:J</infon><infon key="name_2">surname:Zhang;given-names:W</infon><infon key="pub-id_doi">10.1016/j.ebiom.2022.104055</infon><infon key="section_type">REF</infon><infon key="source">EBioMedicine</infon><infon key="type">ref</infon><infon key="volume">80</infon><infon key="year">2022</infon><offset>22655</offset><text>Gut dysbiosis in rheumatic diseases: A systematic review and meta-analysis of 92 observational studies</text></passage><passage><infon key="issue">11</infon><infon key="name_0">surname:Godha;given-names:Y</infon><infon key="name_1">surname:Kumar;given-names:S</infon><infon key="name_2">surname:Wanjari;given-names:A</infon><infon key="pub-id_doi">10.7759/cureus.49458</infon><infon key="section_type">REF</infon><infon key="source">Cureus</infon><infon key="type">ref</infon><infon key="volume">15</infon><infon key="year">2023</infon><offset>22758</offset><text>Role of gut microbiota in the development and management of rheumatoid arthritis: A narrative review</text></passage><passage><infon key="issue">1</infon><infon key="name_0">surname:Jin;given-names:J</infon><infon key="name_1">surname:Cai;given-names:X</infon><infon key="name_2">surname:Rao;given-names:P</infon><infon key="name_3">surname:Xu;given-names:J</infon><infon key="name_4">surname:Li;given-names:J</infon><infon key="pub-id_doi">10.1016/j.berh.2025.102035</infon><infon key="section_type">REF</infon><infon key="source">Best Pract Res Clin Rheumatol</infon><infon key="type">ref</infon><infon key="volume">39</infon><infon key="year">2025</infon><offset>22859</offset><text>Microbiota and immune dynamics in rheumatoid arthritis: mechanisms and therapeutic potential</text></passage><passage><infon key="fpage">9</infon><infon key="issue">1</infon><infon key="lpage">23</infon><infon key="name_0">surname:Miyauchi;given-names:E</infon><infon key="name_1">surname:Shimokawa;given-names:C</infon><infon key="name_2">surname:Steimle;given-names:A</infon><infon key="name_3">surname:Desai;given-names:MS</infon><infon key="name_4">surname:Ohno;given-names:H</infon><infon key="pub-id_doi">10.1038/s41577-022-00727-y</infon><infon key="pub-id_pmid">35534624</infon><infon key="section_type">REF</infon><infon key="source">Nat Rev Immunol</infon><infon key="type">ref</infon><infon key="volume">23</infon><infon key="year">2023</infon><offset>22952</offset><text>The impact of the gut microbiome on extra-intestinal autoimmune diseases</text></passage><passage><infon key="fpage">25180</infon><infon key="issue">29</infon><infon key="lpage">25183</infon><infon key="name_0">surname:Shin;given-names:YH</infon><infon key="name_1">surname:Bang;given-names:S</infon><infon key="name_2">surname:Xavier;given-names:R</infon><infon key="name_3">surname:Clardy;given-names:J</infon><infon key="pub-id_doi">10.1021/jacs.5c08613</infon><infon key="pub-id_pmid">40650585</infon><infon key="section_type">REF</infon><infon key="source">J Am Chem Soc</infon><infon key="type">ref</infon><infon key="volume">147</infon><infon key="year">2025</infon><offset>23025</offset><text>Eggerthella lenta produces a cryptic pro-inflammatory lipid</text></passage><passage><infon key="name_0">surname:Xu;given-names:X</infon><infon key="name_1">surname:Zhou;given-names:J</infon><infon key="name_2">surname:Xie;given-names:H</infon><infon key="pub-id_doi">10.3389/fimmu.2025.1610254</infon><infon key="section_type">REF</infon><infon key="source">Front Immunol</infon><infon key="type">ref</infon><infon key="volume">16</infon><infon key="year">2025</infon><offset>23085</offset><text>Immunomodulatory mechanisms of the gut microbiota and metabolites on regulatory T cells in rheumatoid arthritis</text></passage><passage><infon key="name_0">surname:Christovich;given-names:A</infon><infon key="name_1">surname:Luo;given-names:XM</infon><infon key="pub-id_doi">10.3389/fimmu.2022.946248</infon><infon key="section_type">REF</infon><infon key="source">Front Immunol</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">2022</infon><offset>23197</offset><text>Gut microbiota, leaky gut, and autoimmune diseases</text></passage><passage><infon key="name_0">surname:Habiballah;given-names:DN</infon><infon key="name_1">surname:Li;given-names:F</infon><infon key="name_2">surname:Jiang;given-names:L</infon><infon key="pub-id_doi">10.3389/fimmu.2025.1602235</infon><infon key="section_type">REF</infon><infon key="source">Front Immunol</infon><infon key="type">ref</infon><infon key="volume">16</infon><infon key="year">2025</infon><offset>23248</offset><text>Immune metabolic restoration in systemic lupus erythematosus: the impact of gut microbiota, probiotics, and nutritional synergy</text></passage><passage><infon key="fpage">121</infon><infon key="lpage">132</infon><infon key="name_0">surname:Mattos;given-names:MCO</infon><infon key="name_1">surname:Vivacqua;given-names:A</infon><infon key="name_2">surname:Carneiro;given-names:VMA</infon><infon key="name_3">surname:Grisi;given-names:DC</infon><infon key="name_4">surname:Guimarães;given-names:MDCM</infon><infon key="pub-id_doi">10.1007/978-3-031-79146-8_8</infon><infon key="pub-id_pmid">40111689</infon><infon key="section_type">REF</infon><infon key="source">Adv Exp Med Biol</infon><infon key="type">ref</infon><infon key="volume">1472</infon><infon key="year">2025</infon><offset>23376</offset><text>Interaction of the systemic inflammatory state, inflammatory mediators, and the oral microbiome</text></passage><passage><infon key="name_0">surname:Wang;given-names:X</infon><infon key="name_1">surname:Yuan;given-names:W</infon><infon key="name_2">surname:Yang;given-names:C</infon><infon key="pub-id_doi">10.3389/fimmu.2024.1365554</infon><infon key="section_type">REF</infon><infon key="source">Front Immunol</infon><infon key="type">ref</infon><infon key="volume">15</infon><infon key="year">2024</infon><offset>23472</offset><text>Emerging role of gut microbiota in autoimmune diseases</text></passage><passage><infon key="fpage">7841</infon><infon key="lpage">7854</infon><infon key="name_0">surname:Yang;given-names:L</infon><infon key="name_1">surname:Wang;given-names:K</infon><infon key="name_2">surname:Liu;given-names:B</infon><infon key="pub-id_doi">10.2147/JIR.S517979</infon><infon key="pub-id_pmid">40538777</infon><infon key="section_type">REF</infon><infon key="source">J Inflamm Res</infon><infon key="type">ref</infon><infon key="volume">18</infon><infon key="year">2025</infon><offset>23527</offset><text>Dysbiosis of gut microbiota in ankylosing spondylitis patients</text></passage><passage><infon key="fpage">9</infon><infon key="issue">1</infon><infon key="name_0">surname:You;given-names:K</infon><infon key="name_1">surname:Yang;given-names:L</infon><infon key="name_2">surname:Su;given-names:Z</infon><infon key="pub-id_doi">10.3390/biomedicines13010009</infon><infon key="pub-id_pmid">39857593</infon><infon key="section_type">REF</infon><infon key="source">Biomedicines</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">2024</infon><offset>23590</offset><text>Butyric acid modulates gut microbiota to alleviate inflammation and secondary bone loss in ankylosing spondylitis</text></passage><passage><infon key="fpage">16154</infon><infon key="issue">24</infon><infon key="name_0">surname:Kim;given-names:S</infon><infon key="name_1">surname:Park;given-names:HJ</infon><infon key="name_2">surname:Lee;given-names:SI</infon><infon key="pub-id_doi">10.3390/ijms232416154</infon><infon key="pub-id_pmid">36555792</infon><infon key="section_type">REF</infon><infon key="source">Int J Mol Sci</infon><infon key="type">ref</infon><infon key="volume">23</infon><infon key="year">2022</infon><offset>23704</offset><text>The microbiome in systemic sclerosis: pathophysiology and therapeutic potential</text></passage><passage><infon key="fpage">325</infon><infon key="issue">2</infon><infon key="lpage">346</infon><infon key="name_0">surname:Li;given-names:J</infon><infon key="name_1">surname:He;given-names:J</infon><infon key="name_2">surname:Kuhn;given-names:KA</infon><infon key="name_3">surname:Li;given-names:Z</infon><infon key="pub-id_doi">10.1016/j.rdc.2025.01.004</infon><infon key="pub-id_pmid">40246443</infon><infon key="section_type">REF</infon><infon key="source">Rheum Dis Clin North Am</infon><infon key="type">ref</infon><infon key="volume">51</infon><infon key="year">2025</infon><offset>23784</offset><text>Animal models informing the role of the microbiome and its metabolites in rheumatoid arthritis</text></passage><passage><infon key="name_0">surname:Ng;given-names:BCK</infon><infon key="name_1">surname:Lassere;given-names:M</infon><infon key="pub-id_doi">10.1016/j.semarthrit.2024.152574</infon><infon key="section_type">REF</infon><infon key="source">Semin Arthritis Rheum</infon><infon key="type">ref</infon><infon key="volume">70</infon><infon key="year">2025</infon><offset>23879</offset><text>The role of the gastrointestinal microbiome on rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and reactive arthritis: A systematic review</text></passage><passage><infon key="issue">1</infon><infon key="name_0">surname:Song;given-names:S</infon><infon key="name_1">surname:Wen;given-names:X</infon><infon key="name_2">surname:Chen;given-names:F</infon><infon key="pub-id_doi">10.1186/s13020-025-01162-6</infon><infon key="section_type">REF</infon><infon key="source">Chin Med</infon><infon key="type">ref</infon><infon key="volume">20</infon><infon key="year">2025</infon><offset>24036</offset><text>Qu-zhuo-tong-bi decoction exerts gouty arthritis therapy by skewing macrophage polarization through butanoate metabolism</text></passage><passage><infon key="fpage">935</infon><infon key="issue">9</infon><infon key="lpage">941</infon><infon key="name_0">surname:Generali;given-names:E</infon><infon key="name_1">surname:Bose;given-names:T</infon><infon key="name_2">surname:Selmi;given-names:C</infon><infon key="name_3">surname:Voncken;given-names:JW</infon><infon key="name_4">surname:Damoiseaux;given-names:JGMC</infon><infon key="pub-id_doi">10.1016/j.autrev.2018.04.002</infon><infon key="pub-id_pmid">30005857</infon><infon key="section_type">REF</infon><infon key="source">Autoimmun Rev</infon><infon key="type">ref</infon><infon key="volume">17</infon><infon key="year">2018</infon><offset>24157</offset><text>Nature versus nurture in the spectrum of rheumatic diseases: classification of spondyloarthritis as autoimmune or autoinflammatory</text></passage><passage><infon key="fpage">4537</infon><infon key="issue">10</infon><infon key="name_0">surname:Joseph;given-names:YD</infon><infon key="name_1">surname:Ladd;given-names:AL</infon><infon key="name_2">surname:Bhutani;given-names:N</infon><infon key="pub-id_doi">10.3390/ijms26104537</infon><infon key="pub-id_pmid">40429679</infon><infon key="section_type">REF</infon><infon key="source">Int J Mol Sci</infon><infon key="type">ref</infon><infon key="volume">26</infon><infon key="year">2025</infon><offset>24288</offset><text>Hand osteoarthritis: molecular mechanisms, randomized controlled trials, and the future of targeted treatment</text></passage><passage><infon key="issue">1</infon><infon key="name_0">surname:Yang;given-names:L</infon><infon key="name_1">surname:You;given-names:K</infon><infon key="name_2">surname:Wang;given-names:K</infon><infon key="pub-id_doi">10.1186/s12967-025-06681-2</infon><infon key="section_type">REF</infon><infon key="source">J Transl Med</infon><infon key="type">ref</infon><infon key="volume">23</infon><infon key="year">2025</infon><offset>24398</offset><text>Limosilactobacillus reuteri prevents progression of ankylosing spondylitis in mice by restoring gut microbiota-metabolism homeostasis</text></passage><passage><infon key="name_0">surname:Fehringer;given-names:M</infon><infon key="name_1">surname:Vogl;given-names:T</infon><infon key="pub-id_doi">10.1016/j.jtauto.2025.100269</infon><infon key="section_type">REF</infon><infon key="source">J Transl Autoimmun</infon><infon key="type">ref</infon><infon key="volume">10</infon><infon key="year">2025</infon><offset>24532</offset><text>Molecular mimicry in the pathogenesis of autoimmune rheumatic diseases</text></passage><passage><infon key="name_0">surname:Yang;given-names:Y</infon><infon key="name_1">surname:Hong;given-names:Q</infon><infon key="name_2">surname:Zhang;given-names:X</infon><infon key="name_3">surname:Liu;given-names:Z</infon><infon key="pub-id_doi">10.3389/fimmu.2024.1331486</infon><infon key="section_type">REF</infon><infon key="source">Front Immunol</infon><infon key="type">ref</infon><infon key="volume">15</infon><infon key="year">2024</infon><offset>24603</offset><text>Rheumatoid arthritis and the intestinal microbiome: probiotics as a potential therapy</text></passage><passage><infon key="fpage">609</infon><infon key="issue">6</infon><infon key="name_0">surname:He;given-names:M</infon><infon key="name_1">surname:Kolhoff;given-names:F</infon><infon key="name_2">surname:Mont;given-names:MA</infon><infon key="name_3">surname:Parvizi;given-names:J</infon><infon key="pub-id_doi">10.3390/antibiotics14060609</infon><infon key="pub-id_pmid">40558199</infon><infon key="section_type">REF</infon><infon key="source">Antibiotics (Basel)</infon><infon key="type">ref</infon><infon key="volume">14</infon><infon key="year">2025</infon><offset>24689</offset><text>Is osteoarthritis a state of joint dysbiosis?</text></passage><passage><infon key="fpage">2261</infon><infon key="issue">14</infon><infon key="name_0">surname:Dipalma;given-names:G</infon><infon key="name_1">surname:Marinelli;given-names:G</infon><infon key="name_2">surname:Ferrante;given-names:L</infon><infon key="pub-id_doi">10.3390/nu17142261</infon><infon key="pub-id_pmid">40732886</infon><infon key="section_type">REF</infon><infon key="source">Nutrients</infon><infon key="type">ref</infon><infon key="volume">17</infon><infon key="year">2025</infon><offset>24735</offset><text>Modulating the gut microbiota to target neuroinflammation, cognition and mood: A systematic review of human studies with relevance to fibromyalgia</text></passage><passage><infon key="fpage">4153</infon><infon key="issue">9</infon><infon key="name_0">surname:Aloisi;given-names:AM</infon><infon key="name_1">surname:Casini;given-names:I</infon><infon key="pub-id_doi">10.3390/ijms26094153</infon><infon key="pub-id_pmid">40362392</infon><infon key="section_type">REF</infon><infon key="source">Int J Mol Sci</infon><infon key="type">ref</infon><infon key="volume">26</infon><infon key="year">2025</infon><offset>24882</offset><text>Fibromyalgia: chronic pain due to a blood dysfunction?</text></passage><passage><infon key="issue">1</infon><infon key="name_0">surname:Pan;given-names:B</infon><infon key="name_1">surname:Guo;given-names:Q</infon><infon key="name_2">surname:Cai;given-names:J</infon><infon key="pub-id_doi">10.1038/s41598-024-79336-9</infon><infon key="section_type">REF</infon><infon key="source">Sci Rep</infon><infon key="type">ref</infon><infon key="volume">14</infon><infon key="year">2024</infon><offset>24937</offset><text>Investigating the causal impact of gut microbiota on arthritis via inflammatory proteins using Mendelian randomization</text></passage><passage><infon key="fpage">3291</infon><infon key="issue">17</infon><infon key="lpage">3301</infon><infon key="name_0">surname:Shan;given-names:L</infon><infon key="name_1">surname:Chelliah;given-names:R</infon><infon key="name_2">surname:Rahman;given-names:SME</infon><infon key="name_3">surname:Hwan Oh;given-names:D</infon><infon key="pub-id_doi">10.1080/10408398.2024.2362412</infon><infon key="pub-id_pmid">38832654</infon><infon key="section_type">REF</infon><infon key="source">Crit Rev Food Sci Nutr</infon><infon key="type">ref</infon><infon key="volume">65</infon><infon key="year">2025</infon><offset>25056</offset><text>Unraveling the gut microbiota's role in rheumatoid arthritis: dietary pathways to modulation and therapeutic potential</text></passage><passage><infon key="fpage">254</infon><infon key="issue">4</infon><infon key="name_0">surname:Tsai;given-names:CC</infon><infon key="name_1">surname:Chu;given-names:TY</infon><infon key="name_2">surname:Hsu;given-names:PC</infon><infon key="name_3">surname:Kuo;given-names:CY</infon><infon key="pub-id_doi">10.3390/cimb47040254</infon><infon key="pub-id_pmid">40699653</infon><infon key="section_type">REF</infon><infon key="source">Curr Issues Mol Biol</infon><infon key="type">ref</infon><infon key="volume">47</infon><infon key="year">2025</infon><offset>25175</offset><text>The role of methyl Canthin-6-one-2-carboxylate in targeting the NLRP3 inflammasome in rheumatoid arthritis treatment</text></passage><passage><infon key="issue">3</infon><infon key="name_0">surname:Wang;given-names:X</infon><infon key="name_1">surname:Xu;given-names:H</infon><infon key="name_2">surname:Chao;given-names:Y</infon><infon key="pub-id_doi">10.1002/iid3.70183</infon><infon key="section_type">REF</infon><infon key="source">Immun Inflamm Dis</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">2025</infon><offset>25292</offset><text>Integration of metabolomics and 16S ribosomal RNA sequencing to elucidate the pathogenesis of ankylosing spondylitis</text></passage><passage><infon key="fpage">530</infon><infon key="issue">5</infon><infon key="lpage">543</infon><infon key="name_0">surname:Jia;given-names:L</infon><infon key="name_1">surname:Yuan;given-names:J</infon><infon key="name_2">surname:Chen;given-names:Y</infon><infon key="pub-id_doi">10.1080/09637486.2025.2508173</infon><infon key="pub-id_pmid">40401730</infon><infon key="section_type">REF</infon><infon key="source">Int J Food Sci Nutr</infon><infon key="type">ref</infon><infon key="volume">76</infon><infon key="year">2025</infon><offset>25409</offset><text>Lactobacillus kefiranofaciens and its enhancement effect on the anti-inflammatory function of CII/Gln in MIA-induced osteoarthritis by protecting the intestinal barrier and gut microecology</text></passage><passage><infon key="fpage">183</infon><infon key="lpage">192</infon><infon key="name_0">surname:Manasson;given-names:J</infon><infon key="name_1">surname:Abramson;given-names:SB</infon><infon key="name_2">surname:Scher;given-names:JU</infon><infon key="name_3">surname:Hochberg;given-names:MC</infon><infon key="name_4">surname:Gravallese;given-names:EM</infon><infon key="name_5">surname:Smolen;given-names:JS</infon><infon key="section_type">REF</infon><infon key="source">Rheumatology, 2-Volume Set. 22</infon><infon key="type">ref</infon><infon key="year">2022</infon><offset>25599</offset><text>The microbiome in rheumatic diseases</text></passage><passage><infon key="fpage">242</infon><infon key="issue">2</infon><infon key="lpage">254</infon><infon key="name_0">surname:Manasson;given-names:J</infon><infon key="name_1">surname:Shen;given-names:N</infon><infon key="name_2">surname:Garcia Ferrer;given-names:HR</infon><infon key="pub-id_doi">10.1002/art.40359</infon><infon key="pub-id_pmid">29073348</infon><infon key="section_type">REF</infon><infon key="source">Arthritis Rheumatol</infon><infon key="type">ref</infon><infon key="volume">70</infon><infon key="year">2018</infon><offset>25636</offset><text>Gut microbiota perturbations in reactive arthritis and postinfectious spondyloarthritis</text></passage><passage><infon key="fpage">2589</infon><infon key="issue">11</infon><infon key="lpage">2602</infon><infon key="name_0">surname:Minerbi;given-names:A</infon><infon key="name_1">surname:Gonzalez;given-names:E</infon><infon key="name_2">surname:Brereton;given-names:NJB</infon><infon key="pub-id_doi">10.1097/j.pain.0000000000001640</infon><infon key="pub-id_pmid">31219947</infon><infon key="section_type">REF</infon><infon key="source">Pain</infon><infon key="type">ref</infon><infon key="volume">160</infon><infon key="year">2019</infon><offset>25724</offset><text>Altered microbiome composition in individuals with fibromyalgia</text></passage><passage><infon key="fpage">870</infon><infon key="issue">2</infon><infon key="lpage">879</infon><infon key="name_0">surname:Ahmed;given-names:S</infon><infon key="name_1">surname:Mahapatra;given-names:S</infon><infon key="name_2">surname:Mishra;given-names:R</infon><infon key="pub-id_doi">10.1093/rheumatology/keae165</infon><infon key="section_type">REF</infon><infon key="source">Rheumatol (Oxf Engl)</infon><infon key="type">ref</infon><infon key="volume">64</infon><infon key="year">2025</infon><offset>25788</offset><text>16S RNA-based metagenomics reveal previously unreported gut microbiota associated with reactive arthritis and undifferentiated peripheral spondyloarthritis</text></passage><passage><infon key="issue">1</infon><infon key="name_0">surname:Zhang;given-names:L</infon><infon key="name_1">surname:Liu;given-names:G</infon><infon key="name_2">surname:Huang;given-names:X</infon><infon key="name_3">surname:He;given-names:F</infon><infon key="pub-id_doi">10.1186/s12877-025-05885-x</infon><infon key="section_type">REF</infon><infon key="source">BMC Geriatr</infon><infon key="type">ref</infon><infon key="volume">25</infon><infon key="year">2025</infon><offset>25944</offset><text>Effects of protein supplementation on muscle mass, muscle strength, and physical performance in older adults with physical inactivity: a systematic review and meta-analysis</text></passage><passage><infon key="name_0">surname:Zhao;given-names:T</infon><infon key="name_1">surname:Wei;given-names:Y</infon><infon key="name_2">surname:Zhu;given-names:Y</infon><infon key="pub-id_doi">10.3389/fimmu.2022.1007165</infon><infon key="section_type">REF</infon><infon key="source">Front Immunol</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">2022</infon><offset>26117</offset><text>Gut microbiota and rheumatoid arthritis: from pathogenesis to novel therapeutic opportunities</text></passage><passage><infon key="name_0">surname:Lin;given-names:T</infon><infon key="name_1">surname:Xu;given-names:Z</infon><infon key="name_2">surname:Chen;given-names:J</infon><infon key="pub-id_doi">10.3389/fmicb.2025.1589331</infon><infon key="section_type">REF</infon><infon key="source">Front Microbiol</infon><infon key="type">ref</infon><infon key="volume">16</infon><infon key="year">2025</infon><offset>26211</offset><text>Bibliometric and visualized analysis of the relationship between rheumatoid arthritis and periodontitis-related bacteria using CiteSpace software</text></passage><passage><infon key="fpage">185</infon><infon key="lpage">199</infon><infon key="name_0">surname:Yu;given-names:X</infon><infon key="name_1">surname:Mankia;given-names:K</infon><infon key="name_2">surname:Do;given-names:T</infon><infon key="name_3">surname:Meade;given-names:J</infon><infon key="pub-id_doi">10.1007/978-3-031-79146-8_12</infon><infon key="pub-id_pmid">40111693</infon><infon key="section_type">REF</infon><infon key="source">Adv Exp Med Biol</infon><infon key="type">ref</infon><infon key="volume">1472</infon><infon key="year">2025</infon><offset>26357</offset><text>Oral microbiome dysbiosis and citrullination in rheumatoid arthritis</text></passage><passage><infon key="fpage">1603</infon><infon key="issue">9</infon><infon key="name_0">surname:Kupczyk;given-names:D</infon><infon key="name_1">surname:Bilski;given-names:R</infon><infon key="name_2">surname:Szeleszczuk;given-names:Ł</infon><infon key="name_3">surname:Mądra-Gackowska;given-names:K</infon><infon key="name_4">surname:Studzińska;given-names:R</infon><infon key="pub-id_doi">10.3390/nu17091603</infon><infon key="pub-id_pmid">40362911</infon><infon key="section_type">REF</infon><infon key="source">Nutrients</infon><infon key="type">ref</infon><infon key="volume">17</infon><infon key="year">2025</infon><offset>26426</offset><text>The role of diet in modulating inflammation and oxidative stress in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis</text></passage><passage><infon key="fpage">2387</infon><infon key="issue">12</infon><infon key="name_0">surname:Picchianti Diamanti;given-names:A</infon><infon key="name_1">surname:Panebianco;given-names:C</infon><infon key="name_2">surname:Di Gioia;given-names:V</infon><infon key="pub-id_doi">10.3390/microorganisms12122387</infon><infon key="pub-id_pmid">39770590</infon><infon key="section_type">REF</infon><infon key="source">Microorganisms</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="year">2024</infon><offset>26564</offset><text>A case series report on the effect of tofacitinib on joint inflammation and gut microbiota composition in psoriatic arthritis patients naive to biologic agents</text></passage><passage><infon key="issue">1</infon><infon key="name_0">surname:Guan;given-names:Y</infon><infon key="name_1">surname:Li;given-names:F</infon><infon key="name_2">surname:Li;given-names:N</infon><infon key="name_3">surname:Yang;given-names:P</infon><infon key="pub-id_doi">10.1186/s12974-024-03123-6</infon><infon key="section_type">REF</infon><infon key="source">J Neuroinflammation</infon><infon key="type">ref</infon><infon key="volume">21</infon><infon key="year">2024</infon><offset>26724</offset><text>Decoding Behcet's uveitis: an In-depth review of pathogenesis and therapeutic advances</text></passage><passage><infon key="fpage">569</infon><infon key="issue">4</infon><infon key="name_0">surname:Stoll;given-names:ML</infon><infon key="name_1">surname:DeQuattro;given-names:K</infon><infon key="name_2">surname:Li;given-names:Z</infon><infon key="pub-id_doi">10.3390/children9040569</infon><infon key="pub-id_pmid">35455612</infon><infon key="section_type">REF</infon><infon key="source">Children (Basel)</infon><infon key="type">ref</infon><infon key="volume">9</infon><infon key="year">2022</infon><offset>26811</offset><text>Impact of HLA-B27 and disease status on the gut microbiome of the offspring of ankylosing spondylitis patients</text></passage><passage><infon key="fpage">11741</infon><infon key="lpage">11752</infon><infon key="name_0">surname:Yuan;given-names:YX</infon><infon key="name_1">surname:Feng;given-names:SR</infon><infon key="name_2">surname:Wu;given-names:AY</infon><infon key="pub-id_doi">10.2147/JIR.S496991</infon><infon key="pub-id_pmid">39741755</infon><infon key="section_type">REF</infon><infon key="source">J Inflamm Res</infon><infon key="type">ref</infon><infon key="volume">17</infon><infon key="year">2024</infon><offset>26922</offset><text>Influence of TNF-alpha inhibitors on gut microbiota and immune modulation in treating ankylosing spondylitis: insights into therapeutic mechanisms and clinical implications</text></passage><passage><infon key="fpage">715</infon><infon key="issue">4</infon><infon key="lpage">727</infon><infon key="name_0">surname:Duarte Luiz;given-names:J</infon><infon key="name_1">surname:Manassi;given-names:C</infon><infon key="name_2">surname:Magnani;given-names:M</infon><infon key="name_3">surname:Cruz;given-names:AGD</infon><infon key="name_4">surname:Pimentel;given-names:TC</infon><infon key="name_5">surname:Verruck;given-names:S</infon><infon key="pub-id_doi">10.1080/10408398.2023.2280247</infon><infon key="pub-id_pmid">37950651</infon><infon key="section_type">REF</infon><infon key="source">Crit Rev Food Sci Nutr</infon><infon key="type">ref</infon><infon key="volume">65</infon><infon key="year">2025</infon><offset>27095</offset><text>Lactiplantibacillus plantarum as a promising adjuvant for neurological disorders therapy through the brain-gut axis and related action pathways</text></passage><passage><infon key="name_0">surname:Deng;given-names:C</infon><infon key="name_1">surname:Xiao;given-names:Q</infon><infon key="name_2">surname:Fei;given-names:Y</infon><infon key="pub-id_doi">10.3389/fimmu.2022.918619</infon><infon key="section_type">REF</infon><infon key="source">Front Immunol</infon><infon key="type">ref</infon><infon key="volume">13</infon><infon key="year">2022</infon><offset>27239</offset><text>A glimpse into the microbiome of Sjogren's syndrome</text></passage><passage><infon key="issue">7</infon><infon key="name_0">surname:Manasson;given-names:J</infon><infon key="name_1">surname:Blank;given-names:RB</infon><infon key="name_2">surname:Scher;given-names:JU</infon><infon key="pub-id_doi">10.1136/annrheumdis-2020-218327</infon><infon key="section_type">REF</infon><infon key="source">Ann Rheum Dis</infon><infon key="type">ref</infon><infon key="volume">81</infon><infon key="year">2022</infon><offset>27291</offset><text>Response to: 'microbiome in Sjogren's syndrome: here we are' by van der Meulen et al.</text></passage><passage><infon key="issue">1</infon><infon key="name_0">surname:Tseng;given-names:YC</infon><infon key="name_1">surname:Yang;given-names:HY</infon><infon key="name_2">surname:Lin;given-names:WT</infon><infon key="pub-id_doi">10.1038/s41522-021-00192-w</infon><infon key="section_type">REF</infon><infon key="source">NPJ Biofilms Microbiomes</infon><infon key="type">ref</infon><infon key="volume">7</infon><infon key="year">2021</infon><offset>27377</offset><text>Salivary dysbiosis in Sjogren's syndrome and a commensal-mediated immunomodulatory effect of salivary gland epithelial cells</text></passage><passage><infon key="fpage">213</infon><infon key="issue">2</infon><infon key="lpage">231</infon><infon key="name_0">surname:Bellocchi;given-names:C</infon><infon key="name_1">surname:Volkmann;given-names:ER</infon><infon key="pub-id_doi">10.1016/j.rdc.2025.01.002</infon><infon key="pub-id_pmid">40246439</infon><infon key="section_type">REF</infon><infon key="source">Rheum Dis Clin North Am</infon><infon key="type">ref</infon><infon key="volume">51</infon><infon key="year">2025</infon><offset>27502</offset><text>Advancing gastrointestinal microbiota research in systemic sclerosis: lessons learned from prior research and opportunities to accelerate discovery</text></passage><passage><infon key="name_0">surname:Liang;given-names:M</infon><infon key="name_1">surname:Deng;given-names:Z</infon><infon key="name_2">surname:Wu;given-names:W</infon><infon key="name_3">surname:Dong;given-names:Q</infon><infon key="name_4">surname:Fan;given-names:J</infon><infon key="pub-id_doi">10.1016/j.cyto.2025.156959</infon><infon key="section_type">REF</infon><infon key="source">Cytokine</infon><infon key="type">ref</infon><infon key="volume">191</infon><infon key="year">2025</infon><offset>27650</offset><text>Study on the correlation between intestinal flora and cytokines in children with Henoch-Schonlein purpura</text></passage><passage><infon key="name_0">surname:Sun;given-names:N</infon><infon key="name_1">surname:Zhao;given-names:Y</infon><infon key="name_2">surname:Zhang;given-names:A</infon><infon key="name_3">surname:He;given-names:Y</infon><infon key="pub-id_doi">10.3389/fcimb.2025.1605860</infon><infon key="section_type">REF</infon><infon key="source">Front Cell Infect Microbiol</infon><infon key="type">ref</infon><infon key="volume">15</infon><infon key="year">2025</infon><offset>27756</offset><text>Gut microbiota and osteoarthritis: epidemiology, mechanistic analysis, and new horizons for pharmacological interventions</text></passage><passage><infon key="name_0">surname:Wang;given-names:Z</infon><infon key="name_1">surname:Li;given-names:Y</infon><infon key="name_2">surname:Liao;given-names:W</infon><infon key="pub-id_doi">10.3389/fcimb.2022.935723</infon><infon key="section_type">REF</infon><infon key="source">Front Cell Infect Microbiol</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="year">2022</infon><offset>27878</offset><text>Gut microbiota remodeling: A promising therapeutic strategy to confront hyperuricemia and gout</text></passage><passage><infon key="name_0">surname:Britton;given-names:GJ</infon><infon key="name_1">surname:Mogno;given-names:I</infon><infon key="name_2">surname:Chen-Liaw;given-names:A</infon><infon key="pub-id_doi">10.1101/2025.01.14.633015</infon><infon key="section_type">REF</infon><infon key="type">ref</infon><infon key="year">2025</infon><offset>27973</offset><text>Inflammatory disease microbiomes share a functional pathogenicity predicted by C-reactive protein  bioRxiv</text></passage><passage><infon key="fpage">7281</infon><infon key="issue">15</infon><infon key="name_0">surname:Carrillo-Serradell;given-names:L</infon><infon key="name_1">surname:Liu-Tindall;given-names:J</infon><infon key="name_2">surname:Planells-Romeo;given-names:V</infon><infon key="pub-id_doi">10.3390/ijms26157281</infon><infon key="pub-id_pmid">40806413</infon><infon key="section_type">REF</infon><infon key="source">Int J Mol Sci</infon><infon key="type">ref</infon><infon key="volume">26</infon><infon key="year">2025</infon><offset>28080</offset><text>The human mycobiome: composition, immune interactions, and impact on disease</text></passage><passage><infon key="fpage">2187</infon><infon key="issue">13</infon><infon key="name_0">surname:Zdybel;given-names:K</infon><infon key="name_1">surname:Śliwka;given-names:A</infon><infon key="name_2">surname:Polak-Berecka;given-names:M</infon><infon key="name_3">surname:Polak;given-names:P</infon><infon key="name_4">surname:Waśko;given-names:A</infon><infon key="pub-id_doi">10.3390/nu17132187</infon><infon key="pub-id_pmid">40647290</infon><infon key="section_type">REF</infon><infon key="source">Nutrients</infon><infon key="type">ref</infon><infon key="volume">17</infon><infon key="year">2025</infon><offset>28157</offset><text>Postbiotics formulation and therapeutic effect in inflammation: A systematic review</text></passage><passage><infon key="fpage">2188</infon><infon key="issue">24</infon><infon key="lpage">2196</infon><infon key="name_0">surname:Fernandez;given-names:E</infon><infon key="name_1">surname:Wargo;given-names:JA</infon><infon key="name_2">surname:Helmink;given-names:BA</infon><infon key="pub-id_doi">10.1001/jama.2025.2191</infon><infon key="pub-id_pmid">40354071</infon><infon key="section_type">REF</infon><infon key="source">JAMA</infon><infon key="type">ref</infon><infon key="volume">333</infon><infon key="year">2025</infon><offset>28241</offset><text>The microbiome and cancer: A translational science review</text></passage><passage><infon key="issue">3</infon><infon key="name_0">surname:Cesaro;given-names:A</infon><infon key="name_1">surname:Broset;given-names:E</infon><infon key="name_2">surname:Salimando;given-names:GJ</infon><infon key="pub-id_doi">10.1016/j.xcrp.2025.102458</infon><infon key="section_type">REF</infon><infon key="source">Cell Rep Phys Sci</infon><infon key="type">ref</infon><infon key="volume">6</infon><infon key="year">2025</infon><offset>28299</offset><text>Using synthetic biology to understand the gut-brain axis</text></passage><passage><infon key="fpage">203</infon><infon key="issue">2</infon><infon key="lpage">213</infon><infon key="name_0">surname:Neumeister;given-names:MW</infon><infon key="name_1">surname:Neumeister;given-names:EL</infon><infon key="pub-id_doi">10.1016/j.cps.2019.12.007</infon><infon key="pub-id_pmid">32115047</infon><infon key="section_type">REF</infon><infon key="source">Clin Plast Surg</infon><infon key="type">ref</infon><infon key="volume">47</infon><infon key="year">2020</infon><offset>28356</offset><text>Fibromyalgia</text></passage><passage><infon key="issue">18</infon><infon key="name_0">surname:Guo;given-names:X</infon><infon key="name_1">surname:Guo;given-names:L</infon><infon key="name_2">surname:Lu;given-names:QZ</infon><infon key="pub-id_doi">10.3748/wjg.v31.i18.105495</infon><infon key="section_type">REF</infon><infon key="source">World J Gastroenterol</infon><infon key="type">ref</infon><infon key="volume">31</infon><infon key="year">2025</infon><offset>28369</offset><text>Effect of electroacupuncture combined with Tuina therapy on gut microbiota in patients with knee osteoarthritis</text></passage><passage><infon key="fpage">227</infon><infon key="issue">5</infon><infon key="name_0">surname:Meijers;given-names:B</infon><infon key="name_1">surname:Zadora;given-names:W</infon><infon key="name_2">surname:Lowenstein;given-names:J</infon><infon key="pub-id_doi">10.3390/toxins16050227</infon><infon key="pub-id_pmid">38787079</infon><infon key="section_type">REF</infon><infon key="source">Toxins (Basel)</infon><infon key="type">ref</infon><infon key="volume">16</infon><infon key="year">2024</infon><offset>28481</offset><text>A historical perspective on uremia and uremic toxins</text></passage><passage><infon key="name_0">surname:Tong;given-names:S</infon><infon key="name_1">surname:Zhang;given-names:P</infon><infon key="name_2">surname:Cheng;given-names:Q</infon><infon key="pub-id_doi">10.3389/fcimb.2022.1051682</infon><infon key="section_type">REF</infon><infon key="source">Front Cell Infect Microbiol</infon><infon key="type">ref</infon><infon key="volume">12</infon><infon key="year">2022</infon><offset>28534</offset><text>The role of gut microbiota in gout: is gut microbiota a potential target for gout treatment</text></passage><passage><infon key="fpage">233</infon><infon key="issue">2</infon><infon key="lpage">282</infon><infon key="name_0">surname:Cole;given-names:LD</infon><infon key="name_1">surname:Kuhn;given-names:KA</infon><infon key="pub-id_doi">10.1016/j.rdc.2025.01.005</infon><infon key="pub-id_pmid">40246440</infon><infon key="section_type">REF</infon><infon key="source">Rheum Dis Clin North Am</infon><infon key="type">ref</infon><infon key="volume">51</infon><infon key="year">2025</infon><offset>28626</offset><text>It takes a village: juvenile idiopathic arthritis and the microbiome</text></passage><passage><infon key="fpage">32</infon><infon key="lpage">44</infon><infon key="name_0">surname:He;given-names:H</infon><infon key="name_1">surname:Dong;given-names:X</infon><infon key="name_2">surname:Cao;given-names:L</infon><infon key="pub-id_doi">10.1016/j.bioactmat.2025.06.039</infon><infon key="pub-id_pmid">40688025</infon><infon key="section_type">REF</infon><infon key="source">Bioact Mater</infon><infon key="type">ref</infon><infon key="volume">53</infon><infon key="year">2025</infon><offset>28695</offset><text>Oral microbiota-regulating and inflammation-targeted polymersome-hydrogels for RNAi therapy of ulcerative colitis</text></passage><passage><infon key="fpage">160</infon><infon key="issue">1</infon><infon key="name_0">surname:Bilski;given-names:J</infon><infon key="name_1">surname:Pierzchalski;given-names:P</infon><infon key="name_2">surname:Szczepanik;given-names:M</infon><infon key="name_3">surname:Bonior;given-names:J</infon><infon key="name_4">surname:Zoladz;given-names:JA</infon><infon key="pub-id_doi">10.3390/cells11010160</infon><infon key="pub-id_pmid">35011721</infon><infon key="section_type">REF</infon><infon key="source">Cells</infon><infon key="type">ref</infon><infon key="volume">11</infon><infon key="year">2022</infon><offset>28809</offset><text>Multifactorial mechanism of sarcopenia and sarcopenic obesity. Role of physical exercise, microbiota and myokines</text></passage><passage><infon key="fpage">1479</infon><infon key="issue">5</infon><infon key="lpage">1506</infon><infon key="name_0">surname:Belelli;given-names:D</infon><infon key="name_1">surname:Lambert;given-names:JJ</infon><infon key="name_2">surname:Wan;given-names:MLY</infon><infon key="name_3">surname:Monteiro;given-names:AR</infon><infon key="name_4">surname:Nutt;given-names:DJ</infon><infon key="name_5">surname:Swinny;given-names:JD</infon><infon key="pub-id_doi">10.1093/brain/awae413</infon><infon key="pub-id_pmid">39716883</infon><infon key="section_type">REF</infon><infon key="source">Brain</infon><infon key="type">ref</infon><infon key="volume">148</infon><infon key="year">2025</infon><offset>28923</offset><text>From bugs to brain: unravelling the GABA signalling networks in the brain-gut-microbiome axis</text></passage><passage><infon key="file">ar-40-4-413_f001.jpg</infon><infon key="id">f1-ar-40-4-413</infon><infon key="section_type">FIG</infon><infon key="type">fig_caption</infon><offset>29017</offset><text>Dysbiotic gut microbiota and the gut-joint axis mechanism in rheumatic diseases. Schematic representation of the gut-joint axis linking intestinal dysbiosis to systemic inflammation and joint destruction in rheumatic diseases. The illustration depicts the intestinal lumen densely populated by microbial communities. Dysbiosis—characterized by increased Prevotella, Collinsella, Ruminococcus, Clostridioides difficile, and Porphyromonas gingivalis alongside decreased Faecalibacterium, Bifidobacterium, and Lactobacillus—leads to disruption of the intestinal epithelial barrier (“leaky gut”). This increased permeability allows microbial products such as lipopolysaccharides (LPS) to enter the lamina propria and circulation, activating dendritic cells and macrophages via pro-inflammatory cytokines (e.g., IL-6, IL-1β, TNF-α, IL-23). The resulting skew toward Th17 differentiation (via IL-23 and IL-17 signaling) and reduced regulatory Tactivity promotes osteoclastogenesis, synovial inflammation, and bone destruction in joints. The figure integrates intestinal, immune, and skeletal compartments, illustrating the central mechanistic pathway by which gut dysbiosis contributes to rheumatic disease pathogenesis.</text></passage><passage><infon key="file">t1-ar-40-4-413.xml</infon><infon key="id">t1-ar-40-4-413</infon><infon key="section_type">TABLE</infon><infon key="type">table_caption</infon><offset>30242</offset><text>Summary of Microbiota Changes in Rheumatic Diseases</text></passage><passage><infon key="file">t1-ar-40-4-413.xml</infon><infon key="id">t1-ar-40-4-413</infon><infon key="section_type">TABLE</infon><infon key="type">table</infon><infon key="xml">&lt;?xml version=&quot;1.0&quot; encoding=&quot;UTF-8&quot;?&gt;
&lt;table frame=&quot;box&quot; rules=&quot;groups&quot;&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;bold&gt;Disease&lt;/bold&gt;
&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;bold&gt;Increased Bacteria in Disease&lt;/bold&gt;
&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;bold&gt;Decreased Bacteria in Disease&lt;/bold&gt;
&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;bold&gt;Potential Mechanisms and Effects&lt;/bold&gt;
&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Rheumatoid arthritis (RA)&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;italic toggle=&quot;yes&quot;&gt;Prevotella copri, Porphyromonas gingivalis &lt;/italic&gt;(oral)&lt;italic toggle=&quot;yes&quot;&gt;, Aggregatibacter actinomycetemcomitans&lt;/italic&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;italic toggle=&quot;yes&quot;&gt;Faecalibacterium prausnitzii, Roseburia, Bifidobacterium 
&lt;/italic&gt;
&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Molecular mimicry (citrullination, ACPA production), Th17 increase, increased intestinal permeability, systemic inflammation&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Ankylosing spondylitis (AS)&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;italic toggle=&quot;yes&quot;&gt;Ruminococcus gnavus, Klebsiella pneumoniae, Staphylococcus, Escherichia, Streptococcus&lt;/italic&gt;
&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;italic toggle=&quot;yes&quot;&gt;Dialister, Lachnoclostridium, Oscillibacter, Faecalibacterium, Roseburia 
&lt;/italic&gt;
&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;IL-23/IL-17 activation, leaky gut, subclinical gut inflammation, HLA-B27 association&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Psoriatic arthritis (PsA)&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;italic toggle=&quot;yes&quot;&gt;Actinobacteria (Megamonas), Howardella, Methanobrevibacter, Sutterella 
&lt;/italic&gt;
&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;italic toggle=&quot;yes&quot;&gt;Rikenellaceae, Eubacterium brachy, Bacteroidales 
&lt;/italic&gt;
&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;IBD-like dysbiosis, IL-17 increase, reduced bacterial diversity, modulation with tofacitinib&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Systemic lupus erythematosus (SLE)&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;italic toggle=&quot;yes&quot;&gt;Ruminococcus gnavus, Bacteroides thetaiotaomicron, Ruminococcus intestinalis, Akkermansia muciniphila 
&lt;/italic&gt;
&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;italic toggle=&quot;yes&quot;&gt;Firmicutes &lt;/italic&gt;(general decrease),&lt;italic toggle=&quot;yes&quot;&gt; Odoribacter splanchnicus, Bacteroides fragilis&lt;/italic&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Molecular mimicry (dsDNA cross-reaction), Th17/Treg imbalance, leaky gut, IFN-I dysregulation&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Sjögren’s syndrome (SS)&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;italic toggle=&quot;yes&quot;&gt;Lactobacillus salivarius, Bacteroides fragilis, Ruminococcus gnavus, Streptococcus parasanguinis 
&lt;/italic&gt;
&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;italic toggle=&quot;yes&quot;&gt;Faecalibacterium, Haemophilus parainfluenzae, Roseburia 
&lt;/italic&gt;
&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Oral/intestinal dysbiosis, Th17 increase, anti-inflammatory SCFA decrease, systemic activity association&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Systemic sclerosis (SSc)&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;
&lt;italic toggle=&quot;yes&quot;&gt;Fusobacterium, Ruminococcus, Erwinia, Eggerthella lenta, Clostridium bolteae 
&lt;/italic&gt;
&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;italic toggle=&quot;yes&quot;&gt;Bacteroidetes &lt;/italic&gt;(general decrease), &lt;italic toggle=&quot;yes&quot;&gt;Faecalibacterium, Clostridium&lt;/italic&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Th17 induction, homocysteine production, leaky gut, vasculopathy and inflammation&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Osteoarthritis (OA)&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;italic toggle=&quot;yes&quot;&gt;Firmicutes &lt;/italic&gt;(increase),&lt;italic toggle=&quot;yes&quot;&gt; Bilophila, Desulfovibrio, Streptococcus&lt;/italic&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;italic toggle=&quot;yes&quot;&gt;Roseburia, Bacteroidetes &lt;/italic&gt;(general decrease),&lt;italic toggle=&quot;yes&quot;&gt; Bacteroides acidifaciens &lt;/italic&gt;(in non-obese)&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;LPS leakage, metaflammation, SCFA imbalance (acetic acid increase), joint destruction&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Gout disease&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;italic toggle=&quot;yes&quot;&gt;Proteobacteria&lt;/italic&gt; (increase),&lt;italic toggle=&quot;yes&quot;&gt; Verrucomicrobia&lt;/italic&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;&lt;italic toggle=&quot;yes&quot;&gt;Firmicutes &lt;/italic&gt;(decrease),&lt;italic toggle=&quot;yes&quot;&gt; Bifidobacterium&lt;/italic&gt;&lt;/td&gt;&lt;td align=&quot;left&quot; valign=&quot;top&quot; rowspan=&quot;1&quot; colspan=&quot;1&quot;&gt;Uric acid metabolism disruption, purine metabolism abnormalities, alpha diversity decrease&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;
</infon><offset>30294</offset><text>Disease	Increased Bacteria in Disease	Decreased Bacteria in Disease	Potential Mechanisms and Effects	 	Rheumatoid arthritis (RA)	Prevotella copri, Porphyromonas gingivalis (oral), Aggregatibacter actinomycetemcomitans	Faecalibacterium prausnitzii, Roseburia, Bifidobacterium 	 		Molecular mimicry (citrullination, ACPA production), Th17 increase, increased intestinal permeability, systemic inflammation	 	Ankylosing spondylitis (AS)	Ruminococcus gnavus, Klebsiella pneumoniae, Staphylococcus, Escherichia, Streptococcus	Dialister, Lachnoclostridium, Oscillibacter, Faecalibacterium, Roseburia 	 		IL-23/IL-17 activation, leaky gut, subclinical gut inflammation, HLA-B27 association	 	Psoriatic arthritis (PsA)	Actinobacteria (Megamonas), Howardella, Methanobrevibacter, Sutterella 	 		Rikenellaceae, Eubacterium brachy, Bacteroidales 	 		IBD-like dysbiosis, IL-17 increase, reduced bacterial diversity, modulation with tofacitinib	 	Systemic lupus erythematosus (SLE)	Ruminococcus gnavus, Bacteroides thetaiotaomicron, Ruminococcus intestinalis, Akkermansia muciniphila 	 		Firmicutes (general decrease), Odoribacter splanchnicus, Bacteroides fragilis	Molecular mimicry (dsDNA cross-reaction), Th17/Treg imbalance, leaky gut, IFN-I dysregulation	 	Sjögren’s syndrome (SS)	Lactobacillus salivarius, Bacteroides fragilis, Ruminococcus gnavus, Streptococcus parasanguinis 	 		Faecalibacterium, Haemophilus parainfluenzae, Roseburia 	 		Oral/intestinal dysbiosis, Th17 increase, anti-inflammatory SCFA decrease, systemic activity association	 	Systemic sclerosis (SSc)	Fusobacterium, Ruminococcus, Erwinia, Eggerthella lenta, Clostridium bolteae 	 		Bacteroidetes (general decrease), Faecalibacterium, Clostridium	Th17 induction, homocysteine production, leaky gut, vasculopathy and inflammation	 	Osteoarthritis (OA)	Firmicutes (increase), Bilophila, Desulfovibrio, Streptococcus	Roseburia, Bacteroidetes (general decrease), Bacteroides acidifaciens (in non-obese)	LPS leakage, metaflammation, SCFA imbalance (acetic acid increase), joint destruction	 	Gout disease	Proteobacteria (increase), Verrucomicrobia	Firmicutes (decrease), Bifidobacterium	Uric acid metabolism disruption, purine metabolism abnormalities, alpha diversity decrease	 	</text></passage></document>
</collection>